Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00894413 | A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02390934 | Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer(RAD-THYR) | completed | Phase 2 | 13 | Gustave Roussy, Cancer Campus, Grand ParisOTHER |
| 1 |
| Jun 11, 2019 |
| clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT02410382 | Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer | terminated | Phase 2 | 79 | University of ArizonaOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT01604772 | Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | May 1, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03552458 | Effects of Probiotics in Preventing Oral Mucositis | unknown | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03932266 | Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma | unknown | Phase 2 | 73 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT01264328 | Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer(VECTITAX) | completed | Phase 2 | 40 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00765011 | TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer | completed | Phase 2 | 94 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT02764216 | Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary | unknown | Phase 2 | 48 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02946021 | Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema | completed | Phase 1 / Phase 2 | 11 | Tactile MedicalINDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03890185 | Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC | unknown | Phase 2 | 108 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT02216916 | Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy | unknown | Phase 2 | 49 | Yonsei UniversityOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT02472080 | Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study(THYGEMOX) | terminated | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT00248560 | Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | completed | Phase 2 | 36 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00603915 | A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer | completed | Phase 2 | 20 | University Health Network, TorontoOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00750555 | Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer | terminated | Phase 2 | 4 | Geisinger ClinicOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03843671 | Hyperbaric Radiation Sensitization of Head and Neck Cancers | unknown | Phase 2 | 400 | National Baromedical ServicesOTHER | 2 | Feb 18, 2019 | clinicaltrials |
| NCT00045669 | Imatinib Mesylate in Treating Patients With Salivary Gland Cancer | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 2 | Feb 15, 2019 | clinicaltrials |
| NCT03839602 | Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma Patients | completed | Phase 2 | 103 | Sun Yat-sen UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03121313 | Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+ | unknown | Phase 2 | 68 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03283293 | Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT | completed | Phase 2 | 112 | Sun Yat-sen UniversityOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00484601 | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT00068237 | Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer | completed | Phase 2 | 49 | Radiation Therapy Oncology GroupNETWORK | 2 | Feb 5, 2019 | clinicaltrials |
| NCT00318890 | Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 48 | University of Alabama at BirminghamOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT01392235 | Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 58 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT02976883 | [18F]HX4 PET/CT Imaging for Detection of Hypoxia(OXYPET) | completed | Phase 2 | 8 | Nottingham University Hospitals NHS TrustOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01621880 | Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma(BRAIN) | completed | Phase 2 | 112 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT00573989 | Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 27 | Wake Forest University Health SciencesOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01696955 | Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | terminated | Phase 2 | 1 | HiberCell, Inc.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT00084318 | Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck | completed | Phase 2 | 238 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 12, 2018 | clinicaltrials |
| NCT00100828 | Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer | terminated | Phase 2 | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | terminated | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT03744208 | SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 30 | Shi YuankaiUNKNOWN | 0 | Nov 16, 2018 | clinicaltrials |
| NCT01524692 | Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma(ACC) | completed | Phase 2 | 35 | University of VirginiaOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00181168 | Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer | completed | Phase 2 | 63 | Johns Hopkins UniversityOTHER | 2 | Nov 2, 2018 | clinicaltrials |
| NCT03557112 | By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC | unknown | Phase 2 | 180 | Guiyang Medical UniversityOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00006471 | Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT03654612 | Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies(Y-HR2017-025) | unknown | Phase 1 / Phase 2 | 30 | China International Medical FoundationOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT00500760 | Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer | completed | Phase 2 | 153 | AmgenINDUSTRY | 0 | Oct 17, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT00030576 | Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 51 | University Health Network, TorontoOTHER | 1 | Oct 10, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Jun 11, 2019source: clinicaltrials